Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: A single-center cohort study

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 778-785

  Breynaert, Christine ^a   Ferrante, Marc ^a   Fidder, Herma ^b   Van Steen, Kristel ^c   Noman, Maja ^a   Ballet, Vera ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a   Van Assche, Gert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTHRALGIA; ARTICLE; CHEST TIGHTNESS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; FACE ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; INFUSION REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; PARESTHESIA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; UNCONSCIOUSNESS;

ADOLESCENT; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79953791686     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.61     Document Type: Article

References (20)

1. Hanauer SB, Feagan BG, Lichtenstein GR et al Maintenance Infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
2. Sands BE, Blank MA, PatelK et al Long-term treatment ofrectovaginal f stulas in Crohn's disease: response to Infiximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20. (Pubitemid 39335798)
3. Rutgeerts P, Sandborn WJ, Feagan BG et al Infiximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
4. Cheifetz A, Smedley M, Martin S et al Te incidence and management of infusion reactions to Infiximab: a large center experience. Am J Gastroenterol 2003;98:1315-24. (Pubitemid 36741529)
5. Ferrante M, Vermeire S, Fidder H et al Long-term outcome af er Infiximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 219-25.
6. Fidder H, Schnitzler F, Ferrante M et al Long-term safety of Infiximab for the treatment of Infammatory bowel disease: a single-centre cohort study Gut 2009;58:501-8.
7. Lees CW, Ali AI, Tompson AI et al Te safety profile of anti-tumour necrosis factor therapy in Infammatory bowel disease in clinical prac-tice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ter 2009;29:286-97.
8. Schnitzler F, Fidder H, Ferrante M et al Long-term outcome of treatment with Infiximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
9. Ducharme J, Pelletier C, Zacharias R. Te safety of Infiximab infusions in the community setting. Can J Gastroenterol 2010; 24: 307-11.
10. Zabana Y, Domenech E, Manosa M et al Infiximab safety profile and long-term applicability in Infammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ter 2010;31:553-60.
11. Buch MH, Bryer D, Lindsay S et al Shortening infusion times for inf ixi-mab administration. Rheumatology (Oxford) 2006;45:485-6.
12. Salzberg BA KK. Succesful one hour infusions of Infiximab for Crohn's dis-ease patients in an outpatient ofce setting. Presented at Digestive Disease Week 2004.
13. Befrits R Malmström L, ForsellA et al. One hour Infiximab infusions can replace two hour infusion in maintenance treatment of Crohn's disease without shortcomings, in patients treated for up to three years. Gastroen-terology 2008;134:A402.
14. Van Assche G, Vermeire S, Noman M et al Tolerability and safety of ac-celerated Infiximab infusions: a prospective referral central registry and patient survey J Crohn's Colitis 2010;4:429-333.
15. Clare DF, Alexander FC, Mike S et al Accelerated Infiximab infusions are safe and well tolerated in patients with Infammatory bowel disease. Eur J Gastroenterol Hepatol 2009;21:71-5.
16. Remicade SPC http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000240/human-med-001023.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d124 (last updated 27 April 2010).
17. Baert F, Noman M, Vermeire S et al Inffuence of immunogenicity on the long-term Effcacy of Infiximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
18. Moss AC, Fernandez-Becker N, Jo Kim K et al Te impact of Infiximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ter 2008;28:221-7. (Pubitemid 351861971)
19. Colombel JF, Sandborn WJ, Reinisch W et al Infiximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.
20. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al Withdrawal of immunosuppression in Crohn's disease treated with scheduled Infiximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8. (Pubitemid 351790744)